Zamerovimab
Modify Date: 2025-08-27 13:21:43
Zamerovimab structure
|
Common Name | Zamerovimab | ||
|---|---|---|---|---|
| CAS Number | 2419087-87-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZamerovimabZamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies[1]. |
| Name | Zamerovimab |
|---|
| Description | Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Zamerovimab (CTB011; SYN023) (0.001-100 μg/mL, 4 h) 在 CVS 感染的 BSR 细胞中，以剂量依赖性方式诱导细胞毒性，促进病毒清除，也表明细胞毒性与表达 G 蛋白的细胞特异性相关，而这些细胞被 CTB011 靶向[1]。 |
| In Vivo | Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg，右腓肠肌注射，一次，35 天) 可以以剂量依赖性方式增加感染了狂犬病病毒RABV BD06 的叙利亚仓鼠的存活率，在剂量分别为 0.03、0.1、0.3、1.0 mg/kg 时，存活率分别为 58%，83%，100% 和 100%[1]。 |
| References |
| No Any Chemical & Physical Properties |